Skip to Content

'
Jatin J Shah, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001 Ohio State University College of Medicine, Columbus, OH, MD, Medicine
1997 Ohio State University, Columbus, OH, BS, Mechanical Engineering

Postgraduate Training

7/2004-6/2007 Clinical Fellowship, Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, James Foran
7/2002-6/2004 Clinical Residency, Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, Craig Neilsen
7/2001-6/2002 Clinical Internship, Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, Craig Neilsen

Board Certifications

11/2007 American Board of Internal Medicine, Hematology
11/2007 American Board of Internal Medicine, Oncology
8/2004 American Board of Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Member, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2007-present

Institutional Committee Activities

Member, Multiple Myeloma Tissue Bank Steering Committee, Department of Lymphoma/Myeloma, Division of Cancer Medicine, 2007-present

Honors and Awards

2011 Who's Who in America
2007 Outstanding Research Fellow, University of Alabama at Birmingham
2006 Southern Society of Clinical Investigation Young Investigator Award
1993 Alpha Lambda Delta, Freshman Honor Society
1993 Phi eta Sigma, Freshman Honor Society
1992 Leadership Ohio State, Freshman Foundation Scholarship

Professional Memberships

American Association of Cancer Research
Member, 2006-present
American College of Physician- American Society of Internal Medicine
Member, 2001-present
American Medical Association
Member, 1997-present
American Society of Clinical Oncology
Member, 2004-present
American Society of Hematology
Member, 2004-present
American Society of Mechanical Engineers
Member, 1997-2002
National Associations of Inpatient Physicians
Member, 2001-2004
Ohio State Medical Association
Member, 1997-2001
SWOG
Member, 6/2008-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ. Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. Leukemia 28(2):373-83, 2/2014. e-Pub 6/13/2013. PMCID: PMC3874423.
2. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS, Hagemeister F, Fanale M, Oki Y, Pro B, Shah J, Thomas S, Younes A, Hosing C, Zhang L, Newberry KJ, Desai M, Cheng N, Badillo M, Bejarano M, Chen Y, Young KH, Champlin R, Kwak L, Fayad L. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 27(9):1902-9, 9/2013. e-Pub 4/2/2013. PMID: 23545991.
3. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact Of t(11;14)(q13;q32) On The Outcome Of Autologous Hematopoietic Cell Transplantation In Multiple Myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 8/2013. PMID: 23733001.
4. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma; relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 8/2013. PMID: 23648290.
5. Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol, 7/2013. PMID: 23590726.
6. Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, Lobuglio AF, Forero-Torres A. Phase I Study of a Modified Regimen of (90)Yttrium-Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma. Cancer Biother Radiopharm 28(5):370-9, 6/2013. PMID: 23530878.
7. Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ, International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 27(4):780-91, 4/2013. PMID: 23288300.
8. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk 13(2):99-105, 4/2013. e-Pub 12/29/2012. PMCID: PMC3881262.
9. Lee HC, Shah JJ, Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book 2013:302-6, 2013. PMID: 23714530.
10. Younes A, Romaguera J, Fanale M, McLaughlin P, Hagemeister F, Copeland A, Neelapu S, Kwak L, Shah J, de Castro Faria S, Hart S, Wood J, Jayaraman R, Ethirajulu K, Zhu J. Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes. J Clin Oncol 30(33):4161-7, 11/2012. PMID: 22965964.
11. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in pre-clinical models of multiple myeloma. Blood 120(16):3260-70, 10/2012. PMCID: PMC3476538.
12. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 6/2012. PMID: 22015451.
13. Mendoza TR, Koyyalagunta D, Burton AW, Thomas SK, Phan MH, Giralt SA, Shah JJ, Cleeland CS. Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty. J Pain 13(6):564-70, 6/2012. PMCID: PMC3367066.
14. Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, Lin H, Lan Y, Liu Z, He J, Hong S, Thomas S, Shah J, Baladandayuthapani V, Kwak LW, Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med (Berl) 90(6):695-706, 6/2012. PMID: 22207485.
15. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 118(9):2507-15, 5/2012. PMID: 21887685.
16. Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 87(3):272-6, 3/2012. PMID: 22231283.
17. Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplantation in patients aged =70 years with multiple myeloma. Leuk Lymphoma 53(1):118-22, 1/2012. PMID: 21780997.
18. Reed V, Shah J, Medeiros LJ, Ha CS, Mazloom A, Weber DM, Arzu IY, Orlowski RZ, Thomas SK, Shihadeh F, Alexanian R, Dabaja BS. Solitary plasmacytomas: Outcome and prognostic factors after definitive radiation therapy. Cancer 117(19):4468-74, 10/2011. PMID: 21437886.
19. Shah J, Bladé J, Sonneveld P, Harousseau JL, Lantz K, Londhe A, Lowery C, Orlowski RZ. Rapid Early Monoclonal Protein Reduction after Therapy with Bortezomib or Bortezomib and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Myeloma is Associated with a Longer time to Progression. Cancer 117(16):3758-62, 8/2011. PMID: 21328327.
20. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, Leleu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG, on behalf of the International Myeloma Working Group, International Myeloma Working Group, Abildgaard N, Abonour R, Alexanian R, Alsina M, Anderson KC, Attal M, Avet-Loiseau H, Badros A, Baris D, Barlogie B, Bataille R, Beksaç M, Belch A, Ben-Yehuda D, Bensinger B, Leif Bergsagel P, Bird J, Bladé J, Boccadoro M, Cavo M, Chanan-Khan A, Ming Chen W, Child T, Chim J, Chng WJ, Comenzo R, Crowley J, Dalton W, Davies F, de Souza C, Delforge M, Dimopoulos M, Dispenzieri A, Drach J, Drake M, Durie BG, Einsele H, Facon T, Fantl D, Fermand JP, Fonseca R, Gahrton G, García-Sanz R, Gasparetto C, Gertz M, Gibson J, Giralt S, Goldschmidt H, Greipp P, Hajek R, Hardan I, Hari P, Harousseau JL, Hata H, Hattori Y, Heffner T, Ho J, Hungria V, Ida S, Jacobs P, Jagannath S, Johnsen H, Jian H, Joshua D, Jurczyszyn A, Kawano M, Kröger N, Kumar S, Kyle RA, Lacy M, Lahuerta JJ, Landgren O, Laubach J, Lee JH, Leleu X, Lentzsch S, Lokhorst H, Lonial S, Ludwig H, Maiolino A, Mateos M, Mehta J, Mellqvist UH, Merlini G, Mikhael J, Morales AR, Moreau P, Morgan G, Nari H, Munshi N, Niesvizky R, Nouel A, Novis Y, Orlowski R, Palumbo A, Pavlovsky S, Pilarski L, Powles R, Raje N, Vincent Rajkumar S, Reece D, Reiman T, Richardson PG, Roodman D, Rosiñol L, Miguel JS, Sezer O, Shah JJ, Shaughnessy J, Shimizu K, Shustik C, Siegel D, Singhal S, Sonneveld P, Spencer A, Stadtmauer E, Stewart K, Terpos E, Tosi P, Tricot G, Turesson I, Van Camp B, Van Ness B, Van Riet I, Broek IV, Vanderkerken K, Vescio R, Vesole D, Waage A, Wang M, Weber D, Westin J, Wheatley K, Zonder J. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 7/2011. PMID: 21799510.
21. Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang M, Shah JJ, Orlowski RZ. Evidence of a Role for Activation at WNT-B Catenin Signaling in the Resistance of Plasma Cells and Lenalidomide. J Biol Chem 286(13):11009-20, 4/2011. PMCID: PMC3064156.
22. Hunsucker SA, Magarotto V, Kuhn DJ, Kornblau SM, Wang M, Weber DM, Thomas SK, Shah JJ, Voorhees PM, Xie H, Cornfeld M, Nemeth JA, Orlowski RZ. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 152(5):579-92, 3/2011. PMCID: PMC3402914.
23. Yang L, Wang H, Kornblau SM, Graber DA, Zhang N, Matthews JA, Wang M, Weber DM, Thomas SK, Shah JJ, Zhang L, Lu G, Zhao M, Muddasani R, Yoo SY, Baggerly KA, Orlowski RZ. Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. Oncogene, 3/2011. PMID: 21057542.
24. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE. Effect of Long-term Storage in TRIzol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev 19(10):2445-52, 10/2010. PMCID: PMC2966770.
25. Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-1129, 8/2010. PMCID: PMC3414196.
26. Forero-Torres A, Shah J, Wood T, Posey j, Carlisle R, Copigneaux C, Luo FR, Wojtowicz-Ptraga S, Percent I, Saleh M. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR%). Cancer Biother Radiopharm 25(1):13-9, 2/2010. PMID: 20187792.
27. Shah J., Wang W, Harrough VD, Saville W, Meredith R, Shen S, Mueh J, Lister S, Jasthy G, Maggass C, McKay R, Krumdieck M, Tharp C, Winter S, Gregory W, Buchholz S, Awasthi S, Jacobs H, Chung J, Egner AF, Lobuglio and Forero A. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 48(9):1736-44, 2007.
28. Triozzi PL, Shah JJ, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle R, Conry R, LoBuglio AF, Forero A. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity. Cancer Biother Radiopharm 21(6)(6):553-60, 12/2006. PMID: 17257070.
29. Shah JJ, Meredith R, Shen S, Nabors B, Lobuglio A, Yester M, Forero A. Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy. Clin Lymphoma Myeloma 7(3)(3):236-238, 11/2006. PMID: 17229341.
30. Forero A, Shah J, Carlisle R, Triozzi Pl, LoBuglio AF. Wang WQ, Fujimori M, and Conry RM. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm 21(6):561-8, 2006.
31. Mace SE, Shah J. Observation medicine in emergency medicine residency programs. Acad Emerg Med 9(2):169-171, 2002.
32. Wen H, Shah J, and Balaban RS. Hall effect imaging. Biomed Eng 45(1):119-124, 1998.

Abstracts

1. Kazmi S, Lu G, Shah N, Bashir Q, Parmar S, Orlowski RZ, Shah JJ, Hosing CM, Popat U, Dinh YT, Qureshi S, Rondon G, Giralt S, Champlin R, Qazilbash MH. A Comparative Study of the Outcome of High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Standard-Risk Myeloma Treated Concurrently. Blood (ASH Annual Meeting Abstracts) 118 (#4156), 2011.
2. Qazilbash M, Thall PF, Liu P, Orlowski RZ, Bashir Q, Shah N, Kebriaei P, Parmar S, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Shah JJ, De Lima M, Champlin R. A Randomized Phase II Trial of Fludarabine/Melphalan 140 Vs Fludarabine/ Melphalan 100 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 118 (#4108), 2011.
3. Shah JJ, Zonder J, Cohen A, Orlowski RZ, Alexanian R, Thomas SK, Weber DM, Kaufman JL, Harvey D, Walker D, Litwiler K, Karan S, Hilder B, Ptaszynski AM, Lonial S. ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study. Blood (ASH Annual Meeting Abstracts) 118 (#1860), 2011.
4. Pashos CL, Durie BGM, Rifkin R, Terebelo H, Gasparetto C, Mehtra J, Toomey K, Abonour R, Fonseca R, Narang M, Shah JJ, Swern AS, Sullivan KA, Street TK, Khan ZM. Association of Race with Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients. Blood (ASH Annual Meeting Abstracts) 118 (#5070), 2011.
5. Ahmed S, Lin H, Baladandayuthapani V, Khan MA, LU G, Rondon G, Qureshi S, Dinh YT. Bashir Q, Shah N, Parmar S, Hosing CM, Popat U, Giralt SA, Orlowski RZ, Shah JJ, Qazilbash MH. Impact of Non High-Risk Chromosomal Abnormalities on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 118 (#333), 2011.
6. Zheng Y, Yang J, Qian J, Hanabuchi S, Liu Z, Lu Y, He J, Li H, Shah JJ, Lan Y, Yi Q. P/E Selectins and Their Ligand PSGL-1 Are Crucial for Macrophage-Mediated Multiple Myeloma Chemoresistance. Blood (ASH Annual Meeting Abstracts) 118 (#130), 2011.
7. Anas Younes, MD, Michelle A. Fanale, MD, Peter McLaughlin, MD, Amanda Copeland, Joy Zhu, Jatin J Shah, Silvania de Castro Faria. Phase I Study of a Novel Oral JAK-2 Inhibitor SB1518 In Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity In Multiple Lymphoma Subtypes. Journal of Clinical Oncology, 2011.
8. Fowler NH, Neelapu SS, Fanale MA, Rodriguez MA, Pro B, Hagemeister FB, Younes A, Shah JJ, Kwak LW, Rodriguez D, McLaughlin P. Phase II Study with R-FND Followed by 90-Y Ibritumomab Tiuxetan Radioimmunotherapy and Rituximab Maintenance for Untreated High-Risk Follicular Lymphoma. Blood (ASH Annual Meeting Abstracts) 118 (#99), 2011.
9. Lonial S, Cohen A, Zonder J, Benzinger WI, Kaufman JL, Orlowski RZ, Harvey RD, Alexanian R, Thomas SK, Weber DM, Walker D, Hilder B, Ptaszynski A, Shah JJ. The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood (ASH Annual Meeting Abstracts) 118 (#2935), 2011.
10. Pashos CL, Durie BGM, Rifkin R, Terebelo H, Gasparetto C, Mahta J, Toomey K, Abonour R, Fonseca R, Narang M, Shah JJ, Swern AS, Sullivan KA, Street TK, Khan ZM. Variation in Health-Related Quality of Life (HRQOL) Among Multiple Myeloma Patients by Insurance Coverage. Blood (ASH Annual Meeting Abstracts) 118 (#3150), 2011.
11. Vadhan-Raj S, Zhou X, Shah JJ, Benjamin RS, Gladish G. Venous Thromboembolism (VTE) in Patients with Hematologic and Non-Hematologic Malignancies: Incidence and Risk Factors for Recurrent VTE. Blood (ASH Annual Meeting Abstracts) 118 (#2303), 2011.
12. Swaminathan Padmanabhan, Joseph Thaddeus Beck, Kevin R. Kelly, Nikhil C. Munshi, Andy Dzik-Jurasz, Esha Gangolli, Seth Ettenberg, Kelly Miner, Sanela Bilic, Winston Whyte, Fazal Mehdi, Lu-May Chiang, Patricia Liz Rae, Andrew Spencer, Jatin Shah, Kenneth C. Anderson, Francis J. Giles, A. Keith Stewart. A Phase I/II Study of BHQ880, a Novel Osteoblat Activating, Anti-DKK1 Human Monoclonal Antibody, in Relapsed and Refractory Multiple Myeloma (MM) Patients Treated with Zoledronic Acid (Zol) and Anti-Myeloma Therapy (MM Tx). ASH Annual Meeting 2009 (#750), 2010.
13. Luhua Wang, Luis Fayad, Fredrick B. Hagemeister, Sattva Neelapu, Felipe Samaniego, Peter McLaughlin, Barry Samuels, Qing Yi, Barbara Pro, Michelle Fanale, Jatin Shah, Anas Younes, Neda Bell, Robert Knight, Jerome B. Zeldis, Fernando Cabanillas, Larry Kwak, Jorge Romaguera. A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma. ASH Annual Meeting 2009 (#2719), 2010.
14. Shah JJ, Zonder JA, Cohen A, Weber DM, Thomas SK, Wang M, Kaufman JL, Burt SM, Walker D, Freeman B, Rush SA, Ptaszynski A, Orlowski RZ, Lonisl S. A Phase I/II Trial of the KSP Inhibitor ARRY-520 In Relapsed/Refractory Multiple Myeloma. ASH Annual Meeting 2010 116(1959), 2010.
15. Manish Sharma, Peter Thall, Xuemei Wang, Chitra Hosing, Floralyn L Mendoza, Eric Han, Michael Wang, Donna Weber, Jatin Shah, Amin Alousi, Paolo Anderlini, Partow Kebriaei, Issa F Khouri, Uday Popat, Marcos de Lima, Richard E Champlin, Sergio Giralt, Muzaffar Qazilbash. A Randomized Phase II Trial of High-Dose Melphalan, Ascorbic Acid and Arsenic Trioxide with or without Bortezomib in Multiple Myeloma. ASH Annual Meeting 2009 (#2309), 2010.
16. Pfister DG, Cassileth BR, Deng GE, Yeung KS, Lee JS, Garrity D, Cronin A, Lee N, Kraus D, Shaha AR, Shah JJ, Vickers AJ. Acupuncture for Pain and Dysfunction After Neck Dissection: Results of a Randomized Controlled Trial. Journal of Clinical Oncology (ASCO Annual Meeting) 2010:2565-2570, 2010.
17. Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Dinh Y, Qureshi S, Shah JJ, Orlowski RZ, Weber DM, Champlin R, Giralt S, Qazilbash MH. Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma. ASH Annual Meeting Abstracts 2010 116(4569), 2010.
18. Bashir Q, Wei W, Chiattone A, Rondon G, Parmar S, Shah N, Booc EH, Dinh Y, Qureshi S, Shah JJ, Orlowski RZ, Weber DM, Champlin R, Giralt S, Qazilbash MH. Autologous Hematopoietic Cell Transplantation In Multiple Myeloma Patients Age 70 Years and Older. ASH Annual Meeting 2010 116(4576), 2010.
19. Jason R. Westin, Michael A. Thompson, Vince D. Cataldo, Bela B. Toth, Perpetua Sanjorjo, Scott Bourgeois, Camilo Jimenez, William A. Murphy, Michelle Fanale, Luis Fayad, Nathan Fowler, Larry Kwak, Peter McLaughlin, Sattva Neelapu, Barbara Pro, Alma Rodriguez, Jatin Shah, Fredrick B. Hagemeister. Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response. ASH Annual Meeting 2009 (#3922), 2010.
20. Kaufman JL, Shah JJ, Laubach JP, Heffner L, Francis D, Harvey RD, Lewis C, Tighiouart M, Richardson P, Orlowski RZ, Lonial S. Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study. ASH Annual Meeting 2010 116(3034), 2010.
21. Durie BGM, Shah JJ, Abonour R, Gasperetto C, Mehta J, Pashos CL, Toomey K, Narang M, Terebelo H, Camacho F, Swern AS, Street TK, Sullivan KA, Rifkin RM. New US Myeloma Registry (Connect MM(R) - The Multiple Myeloma Disease Registry): Features of Newly Diagnosed Patients In 2010. ASH Annual Meeting 2010 116(5032), 2010.
22. Reed VK, Shah JJ, Mazloom A, Weber DM, Phan J, Orlowski RZ, Thomas SK, Wang M, Alexanian R, Dabaja BS. Outcome and prognostic factors in solitary plasmacytoma. Journal of Clinical Oncology (ASCO Meeting Abstract) (#e18512), 2010.
23. Parmar S, Khan M, Rondon G, Shah N, Bashir Q, Tung S, Shah JJ, Weber DM, Orlowski RZ, Giralt S, Champlin R, Qazilbash M. Outcome of High Dose Melphalan with Autologous Hematopoietic Stem Cell Transplant In Myeloma Associated with AL Amyloidosis. ASH Annual Meeting 2010 116(2400), 2010.
24. Fanale M, Chao-Ming L, McLaughlin P, Romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu S, Shah J, Kwak L, Dong W, Reed V, Dabaja B, Popat U, Younes A. Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP. ASH Annual Meeting 2010 116(2812), 2010.
25. Shah J, Orlowski RZ, Alexanian RA, Wang M, Thomas SK, Qazilbash M, Parmar S, Shah N, Bashir Q, Popat U, Weber DM. Phase 1 Dose-Escalation Study of Multiple Dosing Schedules of the Investigational Drug MLN4924, a Nedd8-Activating Enzyme Inhibitor, In Patients with Relapsed and/or Refractory Multiple Myeloma or Lymphoma. ASH Annual Meeting 2010 116(1948), 2010.
26. Shah JJ, Cohen AD, Zonder JA, Kaufman JL, Burt SM, Freeman BB, Rush S, Ptaszynski AM, Orlowski RZ, Lonial S. Phase I trial of ARRY-520 in relapsed/refractory multiple myeloma (RR MM). Journal of Clinical Oncology (ASCO Meeting Abstract) (#28: 8132), 2010.
27. Saroj Vadhan-Raj, Luis Fayad, Michelle Fanale, Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, Carlos E. Bueso-Ramos, Xiao Zhou, Peter McLaughlin, Nathan Fowler, Jatin Shah, Felipe Samaniego, Anas Younes, Larry Kwak, Jorge Romaguera. Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome. ASH Annual Meeting 2009 (#105), 2010.
28. Qaiser Bashir, Peter Thall, Chitra Hosing, Floralyn L Mendoza, Eric Han, Michael Wang, Jatin Shah, Amin Alousi, Paolo Anderlini, Partow Kebriaei, Issa F. Khouri, Uday Popat, Marcos de Lima, Richard Champlin, Sergio A Giralt, Muzaffar H Qazilbash. Salvage Autologous or Allogeneic Stem Cell Transplantation After the Failure of First Autograft in Patients with Multiple Myeloma. ASH Annual Meeting 2009 (#1186), 2010.
29. Mendoza TR, Koyyalagunta L, Burton AW, Thomas SK, Giralt S, Shah JJ, Ting J, Perez-Toro MR, Cleeland CS. The impact of pain reduction on other symptoms in patients with multiple myeloma-related painful vertebral fracture treated with kyphoplasty or vertebroplasty. Journal of Clinical Oncology (ASCO Meeting Abstract) (#e19536), 2010.
30. Pashos CL, Durie BGM, Rifkin RM, Shah JJ, Street TK, Sullivan KA, Khan ZM. Variation In Health-Related Quality of Life (HRQOL) by ISS Stage and ECOG Status Among Multiple Myeloma Patients. ASH Annual Meeting 2010 116(3828), 2010.
31. Kay B Delasalle, Luhua Wang, Donna Weber, Sergio A. Giralt, Sheeba Thomas, Jatin Shah, Beverly Handy, Robert Z. Orlowski, and Raymond Alexanian. Curability of Multiple Myeloma. Blood 114:3864, 11/2009.
32. Nina Shah, Khawaja Fraz Ahmed, Sofia Qureshi, Jatin Shah, Robert Z Orlowski, Donna M Weber, Chitra Hosing, Uday Popat, Amin Alousi, Richard E Champlin, Sergio Giralt, Muzaffar Qazilbash. Durable Remission with Salvage Autotransplants in Patients with Multiple Myeloma. Blood 114:1227, 11/2009.
33. Sofia Qureshi, Manish Sharma, Chitra Hosing, Floralyn L Mendoza, Jatin Shah, Amin Alousi, Paolo Anderlini, Partow Kebriaei, Issa F Khouri, Uday Popat, Marcos de Lima, Richard E Champlin, Sergio Giralt, Muzaffar H. Qazilbash. Outcome of IgD Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Blood 114:4354, 11/2009.
34. Jatin J Shah, Andrzej J Jakubowiak, Owen A O’Connor, Robert Z Orlowski, Molly Patterson, Donald Harvey, Allison J Berger, Alice McDonald, George Mulligan, Lilli Petruzzelli, Michael D Pickard, Peter G Smith, Karthik Venkatakrishnan, Sagar Lonial. Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. Blood 114:1854, 11/2009.
35. Sheeba K Thomas, Lei Feng, Kay B Delasalle, Michael Wang, Jatin J Shah, Robert Z Orlowski, Raymond Alexanian, and Donna M Weber. Prognostic Factors for Survival After 2-CdA-Based Therapy for Symptomatic Waldenström Macroglobulinemia (WM) Stratify Patients Into Low- and High-Risk Groups. Blood 114:1668, 11/2009.
36. Nina Shah, Donna M Weber, Michael Wang, Sheeba Thomas, Jatin Shah, Sergio Giralt, Raymond Alexanian, Robert Z Orlowski, Muzaffar H. Qazilbash, Tiffany Avery. Survival Disparities Between African-American and Caucasian Patients with Multiple Myeloma Are Blunted in the Era of Novel Therapeutics and Autologous Stem Cell Transplantation. Blood 114:1395, 11/2009.
37. J. J. Shah, A. Londhe, K. C. Lantz, C. Lowery, R. Z. Orlowski; University of Texas M. D. Anderson Cancer Center, Houston, TX; Centocor Ortho Biotech Services LLC, Horsham, PA. Relationship of rapid M protein reduction to outcomes in a trial of pegylated liposomal doxorubicin (PLD) plus bortezomib (B) versus B alone in previously treated multiple myeloma (MM). J Clin Oncol (ASCO Annual Meeting 2009) 27(15(s)):8591, 5/2009.
38. N. Shah, D. Weber, R. Orlowski, M. Wang, S. K. Thomas, T. Richards, S. Giralt, M. Qazilbash, R. Alexanian, J. J. Shah. Role of autologous stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients. J Clin Oncol (ASCO Annual Meeting 2009) 27(15s):8596, 5/2009.
39. Vince D. Cataldo, Michael A. Thompson, Bela B. Toth, Perpetua Sanjorjo, B. Nebiyou Bekele, Camilo Jimenez, William A. Murphy, Auris O. Huen, Rebecca B. Arbuckle, Michelle A. Fanale, Luis E. Fayad, Nathan Fowler, Larry W. Kwak, Peter W. McLaughlin, Sattva S. Neelapu, Barbara Pro, Alma Rodriguez, Jatin Shah, and Fredrick B. Hagemeister. Bone Loss in Patients with Previously Untreated Lymphoma: The Effect of Periodontal Disease on the Use of Zoledronic Acid. Blood 112:5297, 11/2008.
40. Suzanne M. Cole, Rima Saliba, Matteo Pelosini, Floralyn L Mendoza, Donna Weber, Michael Wang, Sheeba Thomas, Robert Z. Orlowski, Jatin Shah, Amin Alousi, Chitra Hosing, Uday Popat, Partow Kebriaei, Paolo Anderlini, Issa F. Khouri, Richard Champlin, Sergio Giralt, and Muzaffar H. Qazilbash. Reduced-Intensity Regimens for Allogeneic Stem Cell Transplantation Improve the Outcome in Advanced Multiple Myeloma. Blood 112:3298, 11/2008.
41. Jorge Romaguera, Luis Fayad, Alma Rodriguez, Fb Hagemeister, Barbara Pro, Peter McLaughlin, Anas Younes, Felipe Samaniego, Jatin Shah, Pamela Weaver, Kim Hartig, Fernando Cabanillas, Larry Kwak, Hagop Kantarjian, and Michael Wang. Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years: Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL). Blood 112:833, 11/2008.
42. Jatin Shah, Joan Blade, Jesus San Miguel, Pieter Sonneveld, Donghan Luo, Keith C Lantz, Colin Lowery, Jean-Luc Harousseau, and Robert Z. Orlowski. The Effect of Bone Marrow Involvement on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib vs Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood 112:5192, 11/2008.
43. Jatin Shah, Joan Blade, Pieter Sonneveld, Jesus San Miguel, Donghan Luo, Keith C Lantz, Colin Lowery, Jean-Luc Harousseau, Robert Z. Orlowski. The Effect of Paraprotein Heavy Chain and Free Light Chain Types on the Efficacy of Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Patients with Relapsed/Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts) 112(5190) (#5190), 11/2008.
44. MN Saleh, I Percent, TE Wood, J Posey III, J Shah, R Carlisle, S Wojtowicz-Praga, A Forero-Torres. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. ASCO 2008 Annual Meeting (#3537), 2008.
45. J. Shah, S. Donegan, D. Wang, F. Robert. Incidence of Venous Thromboembolic Events and Effect on Survival in Patients with Lung Cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18s) (June 20 Supplement) (#18017), 2007.
46. J Shah, J Mueh, J Lister, et al. Safety and Efficacy of retreating follicular NHL with 90 Y Ibritumomab Tiuxetan (Zevalin). Journal of Investigative Medicine 55(1) (#330), 2007.
47. J. Shah, A. Forero, R. Carlisle, et al. Phase 1 Study of an Anti-GD3 Monoclonal Antibody, (KW-2871) in patients with Advanced Metastatic Melanoma. Journal of Investigative Medicine 54(1) (#189), 2006.
48. J. Shah, D. Harrough, W. Saville, et al. Safety and efficacy of retreating follicular non-Hodgkin's lymphoma (NHL) with 90Y ibritumomab tiuxetan. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 24(18s) (June 20 Supplement) (#17528), 2006.
49. A. Forero-Torres, J. Shah et. al. A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL). Blood 106 (#4798), 2005.
50. J. Shah, A. Forero, R. Carlisle, P. Triozzi, A. Lobuglio, T. Kuwabara, A. Teitelbaum, M. Fujimori, M. Conry. Phase 1 Study of an Anti-GD3 Monoclonal Antibody, (KW-2871) in patients with Advanced Metastatic Melanoma. Journal of Clinical Oncology 23(16s) part I of II (June 1 Supplement) (#2556), 2005.
51. J. J. Shah, M. P.V. Gomes, S. R. Deitcher. Thromboelastographic (TEG) Characterization of Patients with Hematologic Malignancy and Chemotherapy Induced Thrombocytopenia (CIT). Blood 104 (#2729), 2004.
52. J. J. Shah, T. Mekhail, C. Comb, A. Leschinsky, C. Moon, P. Rayman, P. Elson, J. Finke, R. M. Bukowski. Renal cell cancer: Correlation of tumor characteristics with peripheral blood T cell NFκB activation and activation induced cell death (AICD). Proc Am Soc Clin Oncol 22:440 (#1766), 2003.

Book Chapters

1. Shah JJ, Orlowski RZ. Bortezomib in Relapsed and Relapsed/Refractory Multiple Myeloma. In: Bortezomib in Relapsed and Relapsed/Refractory Multiple Myeloma. K.C Anderson/P.G. Richardson/I. Ghobrial, 2010.

Manuals, Teaching Aids, Other Teaching Publications

1. Shah J, Richardson P, Mitsaides C. Multiple Myeloma Syllabus: Core Reading Collection for Hematology/Oncology Fellowship, 1/2006.

Grant & Contract Support

Title: Specialized Program of Research Excellence in Multiple Myeloma. Core D: Clinical Trials Core Facility
Funding Source: SPORE
Role: Co-Investigator
Duration: 2010 - 2015
 
Title: Targeting Met Tyrosine Kinase in Multiple Myeloma
Funding Source: Center for Targeted Therapy Disease-Specific Grant in Lymphoma/Myeloma
Role: Co-Principal Investigator
Principal Investigator: Varsha Gondhi, MD. PhD
Duration: 4/1/2008 - 4/1/2010

Last updated: 6/16/2014